Impact of cyclin E overexpression on Smad3 activity in breast cancer cell lines 

References

• Jeruss JS, Sturgis CD, Rademaker AW, Woodruff TK. Downregulation of activin, activin receptors and Smads in high-grade breast cancer. Cancer Res 2003; 63:3783 - 3790
   PubMed Web of Science ®Google Scholar
• Burdette JE, Jeruss JS, Kurley SJ, Lee EJ, Woodruff TK. Activin A mediates growth inhibition and cell cycle arrest through Smads in human breast cancer cells. Cancer Res 2005; 65:7968 - 7975
   PubMed Web of Science ®Google Scholar
• Moustakas A, Pardali K, Gaal A, Heldin CH. Mechanisms of TGFbeta signaling in regulation of cell growth and differentiation. Immunol Lett 2002; 82:85 - 91
   PubMed Web of Science ®Google Scholar
• Feng XH, Liang YY, Liang M, Zhai W, Lin X. Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGFbeta-mediated induction of the CDK inhibitor p15(Ink4B). Mol Cell 2002; 9:133 - 143
   PubMed Web of Science ®Google Scholar
• Ten Dijke P, Goumans MJ, Itoh F, Itoh S. Regulation of cell proliferation by Smad proteins. J Cell Physiol 2002; 191:1 - 16
   PubMed Web of Science ®Google Scholar
• Knudsen ES, Wang JY. Targeting the RB-pathway in cancer therapy. Clin Cancer Res 16:1094 - 1099
   PubMed Web of Science ®Google Scholar
• Park C, Lee I, Kang WK. E2F-1 is a critical modulator of cellular senescence in human cancer. Int J Mol Med 2006; 17:715 - 720
   PubMed Web of Science ®Google Scholar
• Yagi K, Furuhashi M, Aoki H, Goto D, Kuwano H, Sugamura K, et al. c-myc is a downstream target of the Smad pathway. J Biol Chem 2002; 277:854 - 861
   PubMed Web of Science ®Google Scholar
• Yue J, Mulder KM. Transforming growth factor-beta signal transduction in epithelial cells. Pharmacol Ther 2001; 91:1 - 34
   PubMed Web of Science ®Google Scholar
• Jeruss JS, Santiago JY, Woodruff TK. Localization of activin and inhibin subunits, receptors and SMADs in the mouse mammary gland. Mol Cell Endocrinol 2003; 203:185 - 196
   PubMed Web of Science ®Google Scholar
• Chen YG, Hata A, Lo RS, Wotton D, Shi Y, Pavletich N, et al. Determinants of specificity in TGFbeta signal transduction. Genes Dev 1998; 12:2144 - 2152
   PubMed Web of Science ®Google Scholar
• Matsuura I, Denissova NG, Wang G, He D, Long J, Liu F. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 2004; 430:226 - 231
   PubMed Web of Science ®Google Scholar
• Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002; 347:1566 - 1575
   PubMed Web of Science ®Google Scholar
• Aaltonen K, Blomqvist C, Amini RM, Eerola H, Aittomaki K, Heikkila P, et al. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers. Clin Cancer Res 2008; 14:1976 - 1983
   PubMed Web of Science ®Google Scholar
• Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006; 24:1037 - 1044
   PubMed Web of Science ®Google Scholar
• Kang YK, Kim WH, Jang JJ. Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. Hum Pathol 2002; 33:877 - 883
   PubMed Web of Science ®Google Scholar
• Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, et al. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27 and antiestrogens in breast cancer. Cancer Res 2004; 64:3198 - 3208
   PubMed Web of Science ®Google Scholar
• Enders GH. Cyclins in breast cancer: too much of a good thing. Breast Cancer Res 2002; 4:145 - 147
   PubMed Web of Science ®Google Scholar
• Bortner DM, Rosenberg MP. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol 1997; 17:453 - 459
   PubMed Web of Science ®Google Scholar
• Shaye A, Sahin A, Hao Q, Hunt K, Keyomarsi K, Bedrosian I. Cyclin E deregulation is an early event in the development of breast cancer. Breast Cancer Res Treat 2009; 115:651 - 659
   PubMed Web of Science ®Google Scholar
• Akli S, Keyomarsi K. Low-molecular-weight cyclin E: the missing link between biology and clinical outcome. Breast Cancer Res 2004; 6:188 - 191
   PubMed Web of Science ®Google Scholar
• Sgambato A, Camerini A, Collecchi P, Graziani C, Bevilacqua G, Capodanno A, et al. Cyclin E correlates with manganese superoxide dismutase expression and predicts survival in early breast cancer patients receiving adjuvant epirubicin-based chemotherapy. Cancer Sci 2009; 100:1026 - 1033
   PubMed Web of Science ®Google Scholar
• Gray-Bablin J, Zalvide J, Fox MP, Knickerbocker CJ, DeCaprio JA, Keyomarsi K. Cyclin E, a redundant cyclin in breast cancer. Proc Natl Acad Sci USA 1996; 93:15215 - 15220
   PubMed Web of Science ®Google Scholar
• Smith AP, Henze M, Lee JA, Osborn KG, Keck JM, Tedesco D, et al. Deregulated cyclin E promotes p53 loss of heterozygosity and tumorigenesis in the mouse mammary gland. Oncogene 2006; 25:7245 - 7259
   PubMed Web of Science ®Google Scholar
• Resnitzky D, Gossen M, Bujard H, Reed SI. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 1994; 14:1669 - 1679
   PubMed Web of Science ®Google Scholar
• Guo X, Hartley RS. HuR contributes to cyclin E1 deregulation in MCF-7 breast cancer cells. Cancer Res 2006; 66:7948 - 7956
   PubMed Web of Science ®Google Scholar
• Wang L, Shao ZM. Cyclin E expression and prognosis in breast cancer patients: a meta-analysis of published studies. Cancer Invest 2006; 24:581 - 587
   PubMed Web of Science ®Google Scholar
• Akli S, Van Pelt CS, Bui T, Multani AS, Chang S, Johnson D, et al. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res 2007; 67:7212 - 7222
   PubMed Web of Science ®Google Scholar
• Geng Y, Yu Q, Whoriskey W, Dick F, Tsai KY, Ford HL, et al. Expression of cyclins E1 and E2 during mouse development and in neoplasia. Proc Natl Acad Sci USA 2001; 98:13138 - 13143
   PubMed Web of Science ®Google Scholar
• Wingate H, Zhang N, McGarhen MJ, Bedrosian I, Harper JW, Keyomarsi K. The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. J Biol Chem 2005; 280:15148 - 15157
   PubMed Web of Science ®Google Scholar
• Wadler S. Perspectives for cancer therapies with cdk2 inhibitors. Drug Resist Updat 2001; 4:347 - 367
   PubMed Web of Science ®Google Scholar
• Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene 29:4018 - 4032
   PubMed Web of Science ®Google Scholar
• Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003; 3:233 - 245
   PubMed Web of Science ®Google Scholar
• Johnson N, Bentley J, Wang LZ, Newell DR, Robson CN, Shapiro GI, et al. Pre-clinical evaluation of cyclindependent kinase 2 and 1 inhibition in anti-estrogensensitive and resistant breast cancer cells. Br J Cancer 102:342 - 350
   PubMed Web of Science ®Google Scholar